top of page
Abstract Black Wave

Barga, Italy,  10 May 2024: Kaerus CEO Robert Ring will join other global experts in neurodevelopmental disorders next week in Italy at the Gordon Research Conference on Fragile X and Autism-related Disorders. Dr. Ring will present on the company's BK channel modulator program for Fragile X syndrome in Thursday's (May 16th) session entitled Advances in Therapeutics and Clinical Trial Design.

2024-05-09 LinkedIn Post - GRC Conference.png

About the Gordon Research Conference on Fragile X and Autism-related Disorders

 

The Gordon Research Conferences (GRC) provide an international forum for the presentation and discussion of frontier research in the biological, chemical, physical and engineering sciences and their interfaces.

 

The Fragile X and Autism-Related Disorders GRC is a premier, international scientific conference focused on advancing the frontiers of science through the presentation of cutting-edge and unpublished research, prioritizing time for discussion after each talk and fostering informal interactions among scientists of all career stages. The conference program includes a diverse range of speakers and discussion leaders from institutions and organizations worldwide, concentrating on the latest developments in the field.

 

For more information about Fragile X and Autism-Related Disorders GRC, please visit Conference Website

About Kaerus Bioscience

 

Kaerus Bioscience Ltd is a clinical-stage biotechnology company committed to turning scientific advances into treatment realities for patients with rare genetic syndromes of neurodevelopment. Kaerus has developed a pipeline of targeted, small-molecule therapeutics that address an underlying ion channel dysfunction in Fragile X syndrome, the most common inherited cause of intellectual disability and autism globally.

 

For more information about Kaerus, please visit www.kaerusbio.com

bottom of page